The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway

Kana Shimizu(University of Shizuoka), Tatsuya Morimoto(Kyoto Medical Center)
Pharmaceuticals
December 5, 2021
Cited by 10


Related Papers